GLENMARK PHARMACEUTICALS LTD. - 532296 - Notice Of 42Nd Annual General Meeting Of The Company For FY 2019-20 As Required Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Further to our letter dated August 31, 2020, enclosed please find herewith the Notice Convening the 42nd Annual General Meeting scheduled to be held on Tuesday, September 29, 2020 at 2.00 p.m. IST through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in compliance with Ministry of Corporate Affairs Circular No. 20/2020 dated 5th May, 2020, we are enclosing herewith copies of newspaper advertisement titled '42nd Annual General Meeting' published in Financial Express (English) and Loksatta (Marathi). GLENMARK PHARMACEUTICALS LTD. - 532296 - Intimation Of The Date Of 42Nd Annual General Meeting And Book Closure Pursuant To Regulation 42 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
We have to inform you that the 42nd Annual General Meeting (AGM) of Members of the Company is scheduled to be held on Tuesday, September 29, 2020 at 2.00 p.m. through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM'). The copy of the notice will be sent to you in due course. Pursuant to the Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Register of Members and the Share Transfer Books of the Company will remain closed from Saturday, September 19, 2020 to Tuesday, September 29, 2020 (both days inclusive) for the purpose of the AGM and determining the names of the eligible Members for equity dividend.
Buy Glenmark Pharma; target of Rs 576 KRChoksey
KRChoksey is bullish on Glenmark Pharma has recommended buy rating on the stock with a target price of Rs 576 in its research report dated August 20, 2020.
To raise funds, Glenmark to divest stake in drug development arm Ichnos
The pharma company had a debt of Rs 3,602 crore as on June 30, 2020 compared to Rs 3,758 crore on March 31.
Slow US growth and high debt continue to weigh on Glenmark Pharma
Glenmark Pharmaceutical Ltd's stock may just face some pressure as investors are concerned about its high net debt and the growth outlook in the US
Earnings Call Transcript - Q1FY21 for Glenmark Pharmaceuticals
Conference Call with Glenmark Pharma Management and Analysts on Q1FY21 Performance and Outlook. Listen to the full earnings transcript. Glenmark Q1 net jumps over two-fold, revenue up marginally at Rs 2,344.8 cr
"We focussed on controlling costs on all fronts and will continue with these efforts for the remaining part of the financial year," Glenmark Pharmaceuticals Chairman and MD Glenn Saldanha said GLENMARK PHARMACEUTICALS LTD. - 532296 - Outcome Of The Board Meeting - 14Th August, 2020
Sub: Outcome of the Board Meeting - 14th August, 2020 Appointment of Mr. Dipankar Bhattacharjee (DIN: 08770548) as an Additional Director to hold office as an Independent Director of the Company for a period of five years with effect from 14th August, 2020, not liable to retire by rotation, subject to the approval of the members of the Company in the ensuing Annual General Meeting. Recommendation of Appointment of Statutory Auditors: With reference to the captioned subject,the Board of Directors, based on the recommendation of the Audit Committee, have, at their meeting held on 14th August, 2020, recommended the appointment (for the approval of the shareholders) of M/s Suresh Surana & Associates, Chartered Accountants (Firm Registration No.121750W/W-100010) as Statutory Auditors of the Company, as the term of existing auditors M/s Walker Chandiok & Co LLP will end at the conclusion of the ensuing AGM. GLENMARK PHARMACEUTICALS LTD. - 532296 - Unaudited Financial Results (Standalone And Consolidated) For The First Quarter Ended 30Th June, 2020
Unaudited Financial Results (Standalone and Consolidated) for the First Quarter ended 30th June, 2020